ALSO NOTED: Abbott stent gets review; Studies ease finasteride fears; The Pill cuts cancer risk;

> And in other stent news, the FDA plans to schedule an advisory committee meeting to discuss Abbott Laboratories' Xience drug-coated version, already sold overseas. Report

> New studies may ease fears of finasteride, a generic drug that's effective in preventing prostate cancer--but until now was thought to promote fast-growing tumors in those patients who did develop cancer. Release

> The Pill may actually cut cancer risk--up to 12 percent, in fact--provided women don't take it for longer than eight years, according to a new study published in the British Medical Journal. Report

> Natco Pharma has launched a generic version of Lenalid, used to treat Myelo Dysplastic Syndrome. Report

> Venture capitalists are betting big on nanotechnology. Report

And Finally... Pharma companies may be experts at some technologies, but their online advertising is mired in the Internet dark ages. Report

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

THIS WEEK: Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today!

Suggested Articles

North Korean hackers were accused of posing as corporate recruiters in a scheme to breach AstraZeneca's computer systems and steal COVID-19 research.

The FDA has delayed its review of Revance's frown-line injection candidate after it failed to inspect a key manufacturing facility on time.

McKinsey & Company helped guide Purdue's strategy for years and pitched the idea of rebates to distributors for overdoses, according to the NYT.